H.C. Wainwright Upgrades Prelude Therapeutics (PRLD) to Buy, 'attractive entry point'
Tweet Send to a Friend
(Updated - September 19, 2024 7:04 AM EDT)
H.C. Wainwright analyst Robert Burns upgraded Prelude Therapeutics (NASDAQ: PRLD) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
H.C. Wainwright analyst Robert Burns upgraded Prelude Therapeutics (NASDAQ: PRLD) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
